Skip to main content
Log in

Atorvastatin Safety in Kawasaki Disease Patients With Coronary Artery Aneurysms

  • Original Article
  • Published:
Pediatric Cardiology Aims and scope Submit manuscript

A Letter to the Editor to this article was published on 27 September 2013

Abstract

Statins (HMG-CoA reductase inhibitors) may decrease inflammation in postacute Kawasaki disease (KD) complicated by coronary artery aneurysm (CAA) and promote vascular remodeling. There are limited data on their safety in young children. Twenty patients with CAAs after KD (median CAA z-score = +25) were treated with 5/10 mg atorvastatin daily for a median of 2.5 years (range 0.5–6.8) starting at a median of 2.3 years (range 0.3–8.9) after acute KD (median age 9.3 years [range 0.7–14.3]). Compliance with treatment was excellent: only one patient reported minor side effects (joint pain, no change in medication). Average total cholesterol before atorvastatin was 3.73 ± 0.84 mmol/L and after atorvastatin was 3.21 ± 0.46 mmol/L (relative decrease −14 %, p = 0.02); low-density lipoprotein cholesterol was 1.99 ± 0.76 mmol/L before and only 1.49 ± 0.27 mmol/L after (relative decrease −20 %, p = 0.04); high-density lipoprotein was 1.39 ± 0.36 mmol/L before and 1.30 ± 0.27 mmol/L after (relative decrease −4 %, p = 0.35); and triglycerides were 0.71 ± 0.28 mmol/L before and 0.71 ± 0.18 mmol/L after (relative decrease −5 %, p = 0.38). Nine of 20 patients (45 %) experienced at least 1 episode of hypocholesterolemia (total cholesterol <3.1 mmol/L), and 2 patients required atorvastatin dose lowering. Transient mild increase of liver enzymes (aspartate aminotransferase/alanine aminotransferase 45–60 U/L) were seen in 7 of 20 (35 %) patients with no patients experiencing more severe increases. Only one patient experienced increased creatine phosphokinase levels (>500 U/L). Serial measurements of age- and sex-specific percentiles of weight (estimated change: 1.4 [2.7] % per year, p = 0.60), height (estimated change: −3.2 [3.2] % per year, p = 0.32), and body mass index (estimated change: 1.0 [2.9] % per year, p = 0.73) showed no association between anthropomorphic growth and atorvastatin treatment. Atorvastatin use in very young children with KD is safe but should be closely monitored.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Avis HJ, Hutten BA, Gagne C, Langslet G, McCrindle BW, Wiegman A et al (2010) Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol 55:1121–1126

    Article  CAS  PubMed  Google Scholar 

  2. Blankier S, McCrindle BW, Ito S, Yeung RS (2011) The role of atorvastatin in regulating the immune response leading to vascular damage in a model of Kawasaki disease. Clin Exp Immunol 164:193–201

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Carreau V, Girardet JP, Bruckert E (2011) Long-term follow-up of statin treatment in a cohort of children with familial hypercholesterolemia: efficacy and tolerability. Paediatr Drugs 13:267–275

    Article  PubMed  Google Scholar 

  4. Gandelman K, Glue P, Laskey R, Jones J, LaBadie R, Ose L (2011) An 8-week trial investigating the efficacy and tolerability of atorvastatin for children and adolescents with heterozygous familial hypercholesterolemia. Pediatr Cardiol 32:433–441

    Article  PubMed Central  PubMed  Google Scholar 

  5. Hamaoka A, Hamaoka K, Yahata T, Fujii M, Ozawa S, Toiyama K et al (2010) Effects of HMG-CoA reductase inhibitors on continuous post-inflammatory vascular remodeling late after Kawasaki disease. J Cardiol 56:245–253

    Article  PubMed  Google Scholar 

  6. Huang SM, Weng KP, Chang JS, Lee WY, Huang SH, Hsieh KS (2008) Effects of statin therapy in children complicated with coronary arterial abnormality late after Kawasaki disease: a pilot study. Circ J 72:1583–1587

    Article  CAS  PubMed  Google Scholar 

  7. Manlhiot C, Millar K, Golding F, McCrindle BW (2010) Improved classification of coronary artery abnormalities based only on coronary artery z-scores after Kawasaki disease. Pediatr Cardiol 31:242–249

    Article  PubMed  Google Scholar 

  8. Manlhiot C, Niedra E, McCrindle BW (2013) Long-term management of Kawasaki disease: implications for the adult patient. Pediatr Neonatol 54:12–21

    Article  PubMed  Google Scholar 

  9. McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP et al (2007) Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 115:1948–1967

    Article  PubMed  Google Scholar 

  10. Mihos CG, Salas MJ, Santana O (2010) The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review. Cardiol Rev 18:298–304

    Article  PubMed  Google Scholar 

  11. O’Gorman CS, O’Neill MB, Conwell LS (2010) Considering statins for cholesterol-decrease in children if lifestyle and diet changes do not improve their health: a review of the risks and benefits. Vasc Health Risk Manag 7:1–14

    Article  PubMed Central  PubMed  Google Scholar 

  12. O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA et al (2013) ACCF/AHA guideline for the management of ST-increase myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation 127:529–555

    Article  PubMed  Google Scholar 

  13. Smaldone C, Brugaletta S, Pazzano V, Luizzo G (2009) Immunomodulator activity of 3-hydroxy-3-methilglutaryl-CoA inhibitors. Cardiovasc Hematol Agents Med Chem 7:279–294

    Article  CAS  PubMed  Google Scholar 

  14. Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Strandberg T, Tonstad S et al (2010) Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev. doi:10.1002/14651858

    PubMed  Google Scholar 

  15. Weng KP, Ou SF, Lin CC, Hsieh KS (2011) Recent advances in the treatment of Kawasaki disease. J Chin Med Assoc 74:481–484

    Article  CAS  PubMed  Google Scholar 

  16. Zhou Q, Liao JK (2010) Pleiotropic effects of statins: basic research and clinical perspectives. Circ J 74:818–826

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

Brian McCrindle discloses the following potential conflicts of interests regarding this manuscript: consultant for Bristol Myers Squibb, Merck and Eli Lilly, member of data safety and monitoring board for Medpace and receiving research support from Shering Plough and Astra Zeneca.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Brian W. McCrindle.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Niedra, E., Chahal, N., Manlhiot, C. et al. Atorvastatin Safety in Kawasaki Disease Patients With Coronary Artery Aneurysms. Pediatr Cardiol 35, 89–92 (2014). https://doi.org/10.1007/s00246-013-0746-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00246-013-0746-9

Keywords

Navigation